MPL mutations are present in 3–8% of ET [22] and are associated with an increase in both platelet count and serum EPO level, and with both lower Hb level and marrow cellularity than in JAK2V617F-positive ET patients [54,70,71]. The gene discussed is EPO; the disease is essential thrombocythemia.